Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-Dexamethasone (Vel/Dex) Followed by HDT With ASCT

Trial Profile

Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-Dexamethasone (Vel/Dex) Followed by HDT With ASCT

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 May 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 17 Feb 2012 Planned end date changed from 1 Jul 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top